BRIEF-TG Therapeutics Secures An Additional $500 Million In Non-Dilutive Capital From Blue Owl And Expands Share Repurchase Program To $300 Million

Reuters

Mar 19

BRIEF-TG <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Secures An Additional $500 Million In Non-Dilutive Capital From <a href="https://laohu8.com/S/OBDE">Blue Owl</a> And Expands Share Repurchase Program To $300 Million

March 19 (Reuters) - TG Therapeutics Inc TGTX.O:

TG THERAPEUTICS SECURES AN ADDITIONAL $500 MILLION IN NON-DILUTIVE CAPITAL FROM BLUE OWL AND EXPANDS SHARE REPURCHASE PROGRAM TO $300 MILLION
TG THERAPEUTICS INC - ENTERS FIVE-YEAR $750 MILLION CREDIT FACILITY WITH BLUE OWL CAPITAL
TG THERAPEUTICS INC - INCREASES SHARE REPURCHASE PROGRAM TO $300 MILLION

Source text: ID:nGNX9Ptsjn

Further company coverage: TGTX.O

((((Reuters.Briefs@thomsonreuters.com;));))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2620247307"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620247307\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620247307?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 19:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620247307","market":"nz","top_or_hot":-1,"title":"BRIEF-TG Therapeutics Secures An Additional $500 Million In Non-Dilutive Capital From Blue Owl And Expands Share Repurchase Program To $300 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-TG <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Secures An Additional $500 Million In Non-Dilutive Capital From <a href=\"https://laohu8.com/S/OBDE\">Blue Owl</a> And Expands Share Repurchase Program To $300 Million</title></head><body><p><span>March 19 (Reuters)</span><span> - </span>TG Therapeutics Inc <span>TGTX.O</span>:</p><ul><li><p>TG THERAPEUTICS SECURES AN ADDITIONAL $500 MILLION IN NON-DILUTIVE CAPITAL FROM BLUE OWL AND EXPANDS SHARE REPURCHASE PROGRAM TO $300 MILLION</p></li><li><p>TG THERAPEUTICS INC - ENTERS FIVE-YEAR $750 MILLION CREDIT FACILITY WITH BLUE OWL CAPITAL</p></li><li><p>TG THERAPEUTICS INC - INCREASES SHARE REPURCHASE PROGRAM TO $300 MILLION</p></li></ul><p>Source text: <span>ID:nGNX9Ptsjn</span></p><p>Further company coverage: <span>TGTX.O</span></p><p> ((((Reuters.Briefs@thomsonreuters.com;));))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-TG Therapeutics Secures An Additional $500 Million In Non-Dilutive Capital From Blue Owl And Expands Share Repurchase Program To $300 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-TG Therapeutics Secures An Additional $500 Million In Non-Dilutive Capital From Blue Owl And Expands Share Repurchase Program To $300 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-19 19:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-TG <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Secures An Additional $500 Million In Non-Dilutive Capital From <a href=\"https://laohu8.com/S/OBDE\">Blue Owl</a> And Expands Share Repurchase Program To $300 Million</title></head><body><p><span>March 19 (Reuters)</span><span> - </span>TG Therapeutics Inc <span>TGTX.O</span>:</p><ul><li><p>TG THERAPEUTICS SECURES AN ADDITIONAL $500 MILLION IN NON-DILUTIVE CAPITAL FROM BLUE OWL AND EXPANDS SHARE REPURCHASE PROGRAM TO $300 MILLION</p></li><li><p>TG THERAPEUTICS INC - ENTERS FIVE-YEAR $750 MILLION CREDIT FACILITY WITH BLUE OWL CAPITAL</p></li><li><p>TG THERAPEUTICS INC - INCREASES SHARE REPURCHASE PROGRAM TO $300 MILLION</p></li></ul><p>Source text: <span>ID:nGNX9Ptsjn</span></p><p>Further company coverage: <span>TGTX.O</span></p><p> ((((Reuters.Briefs@thomsonreuters.com;));))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUA8DRJSY:1","article_id":"2620247307","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620247307","pubTimestamp":1773921333,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-TG Therapeutics Secures An Additional $500 Million In Non-Dilutive Capital From Blue Owl And Expands Share Repurchase Program To $300 MillionMarch 19 (Reuters) - TG Therapeutics Inc TGTX.O:TG TH","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4588":"碎股","BK4585":"ETF&股票定投概念","TGTX":"TG Therapeutics Inc."},"translate_title":"简介-TG Therapeutics从Blue Owl获得额外5亿美元的非稀释性资本，并将股票回购计划扩大至3亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TGTX":0.9},"content_text":"BRIEF-TG Therapeutics Secures An Additional $500 Million In Non-Dilutive Capital From Blue Owl And Expands Share Repurchase Program To $300 MillionMarch 19 (Reuters) - TG Therapeutics Inc TGTX.O:TG THERAPEUTICS SECURES AN ADDITIONAL $500 MILLION IN NON-DILUTIVE CAPITAL FROM BLUE OWL AND EXPANDS SHARE REPURCHASE PROGRAM TO $300 MILLIONTG THERAPEUTICS INC - ENTERS FIVE-YEAR $750 MILLION CREDIT FACILITY WITH BLUE OWL CAPITALTG THERAPEUTICS INC - INCREASES SHARE REPURCHASE PROGRAM TO $300 MILLIONSource text: ID:nGNX9PtsjnFurther company coverage: TGTX.O ((((Reuters.Briefs@thomsonreuters.com;));))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}